Phase ii study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- And T-cell non-Hodgkin lymphomas

Jonathan W. Friedberg, Daruka Mahadevan, Erin Cebula, Daniel Persky, Izidore Lossos, Amit B. Agarwal, Jung Ah Jung, Richard Burack, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, Hadi Danaee, Steven H. Bernstein

Research output: Contribution to journalArticlepeer-review

158 Scopus citations

Fingerprint Dive into the research topics of 'Phase ii study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- And T-cell non-Hodgkin lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences